Full Press Release Details
SOUTH SAN FRANCISCO, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer and chairman, is scheduled to present at the virtual 2020 Bank of America Securities Health Care Conference.
| Date: | Thursday, May 14, 2020 |
| Time: | 11:40 a.m. Eastern Daylight Time |
A live audio of this webcast will be available through the “Investors & News” section of CytomX's website. An archived replay will be available for 60 days following the event.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational antibody therapeutics, based on our Probody® technology platform, for the treatment of cancer.
PROBODY is a U.S. registered trademark of CytomX Therapeutics.
Investor and Media Contact:
VP, Investor Relations and Corporate Communications